CLL: Navigating Treatment with BTK Inhibitors
Presentation
CancerCoachLive invites you to join 2 expert hematology/oncology clinicians and a CLL patient for a 1-hour live, online, interactive discussion led by led by Dr. Matthew Davids, Associate Professor of Medicine, Harvard Medical School, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute.
This program will cover the challenges associated with BTK-inhibitor use in the treatment of CLL. Panelists will discuss the latest findings on long-term efficacy, side-effect management, and adopting healthy lifestyles to improve outcomes.
Watch this program and you will learn about:
- Available and recommended treatment options for CLL at all stages of disease
- Basic details about available BTK inhibitors from a patient’s perspective
- How patients and their caregivers can help align perspectives with healthcare providers
When you register, you may submit questions to the expert panel.
Living With Chronic Lymphocytic Leukemia (CLL)
We invite you to learn more about:
- Treatment goals for a chronic disease
- New and emerging therapies for CLL
- Side-effect management
- The importance of open communication with your healthcare team
Stephen E. Spurgeon, MD
Associate Professor of Medicine
School of Medicine
Oregon Health & Science University
Hematology/Oncology
Portland, OR
Program Support
Support for this program is provided by Genentech, Inc. & Biogen, Eli Lilly and Company, and Pharmacylics, An AbbVie Company & Janssen Biotech.
Spotlight on Chronic Lymphocytic Leukemia (CLL)
We invite you to learn more about:
- Emerging therapies and clinical trials for CLL
- Managing side effects
- Strategies to improve your quality of life
Nicole Lamanna, MD
Associate Attending, Leukemia Service
Director, Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Medical Center
New York, NY
Program Support
Support for this program provided by: AbbVie Inc. - BeiGene; Eli Lilly and Company - Pharmacyclics - An AbbVie Company & Janssen Biotech - and the Thomas D. Oxley Fund for CLL Patient Education & Support.
George
George
I was born in the inner city of Philadelphia, PA in 1951, I currently live near Dallas, Texas. My professional career in the Information Technology Industry lasted over 40 years prior to my retirement in January 2019. In 2002 I was diagnosed with chronic lymphocytic leukemia (CLL) and many aspects of my life changed forever.
Tracey
Tracey
I was diagnosed with chronic lymphocytic leukemia (CLL) in 2021 after a routine physical after my 50th birthday. It was a complete shock and I was scared and unsure of what my future would look like. With the help of my doctors and The Leukemia & Lymphoma Society (LLS), I feel prepared to make informed decisions about my future.
Michele
Michele
I was recently diagnosed with chronic lymphocytic leukemia (CLL). My mom passed away from pulmonary fibrosis right before Thanksgiving 2022. She never smoked and had none of the risk factors that led to that type of disease. I have a 2½-year-old daughter, and I am an older mom, so I figured I should get a physical to make sure I and my lungs were healthy.